相关实验视频

Updated: May 9, 2026

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

在胃绕道术后,在老鼠中重新编程肠道葡萄糖代谢和血糖控制

Nima Saeidi1, Luca Meoli, Eirini Nestoridi

  • 1Center for Basic and Translational Obesity Research, Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Science (New York, N.Y.)
|July 27, 2013
PubMed
概括

鲁克斯-en-Y胃绕道 (RYGB) 通过改变肠道葡萄糖代谢来改善2型糖尿病. 鲁克斯肢体适应增加的营养暴露,成为葡萄糖吸收和利用的主要地点,有助于血糖控制.

更多相关视频

One-anastomosis Gastric Bypass (OAGB) in Rats08:16

One-anastomosis Gastric Bypass (OAGB) in Rats

Published on: November 10, 2018

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers11:58

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...